The FDA Has Accepted GSK's Supplemental Marketing Application For Jemperli (Dostarlimab) Plus Chemotherapy For Adult Patients With Mismatch Repair Deficient/Microsatellite Instability-high Primary Advanced Or Recurrent Endometrial Cancer.
Portfolio Pulse from Benzinga Newsdesk
The FDA has accepted GSK's supplemental marketing application for Jemperli (dostarlimab) plus chemotherapy for adult patients with mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer. The PDUFA date is set for 23 September under priority review.
June 06, 2023 | 10:19 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GSK's Jemperli marketing application has been accepted by the FDA, potentially expanding the drug's market and increasing revenues.
The FDA's acceptance of GSK's supplemental marketing application for Jemperli indicates a positive step towards the drug's approval for endometrial cancer treatment. This could potentially expand the market for Jemperli and increase GSK's revenues, leading to a positive short-term impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100